TITLE

Look, no strings: publishing industry-funded research

PUB. DATE
September 2001
SOURCE
CMAJ: Canadian Medical Association Journal;9/18/2001, Vol. 165 Issue 6, p733
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Editorial. Discusses drug research by pharmaceutical companies. Controversy over research funding; Argument in favor of industry-funded research.
ACCESSION #
5213260

 

Related Articles

  • Drug Development Costs Soar to Record High Levels. Jarvis, Lisa // Chemical Market Reporter;6/24/2002, Vol. 261 Issue 25, p10 

    Reports on the increased costs of drug development. Factors that influenced the increase; Challenges encountered by pharmaceutical companies concerning drug development; Statement from Janice M. Riechert, senior research fellow at Tufts Center for the Study of Drug Development.

  • Drug Research: Marketing Before Evidence, Sales Before Safety. Kögler, Gesine; Reimann, Verena; Klemperer, David // Deutsches Aerzteblatt International;4/23/2010, Vol. 107 Issue 16, p1 

    The author reflects on the possible bias in the results of drug research. He cites the review of drug research which indicates that those funded by the pharmaceutical industry are likely to report positive results compared to independently funded studies. He further points out that most of the...

  • Addex Pharmaceuticals raises €25 million.  // European Pharmaceutical Executive;Nov/Dec2006, p12 

    The article reports on the additional 25 million euro funding raised by Addex Pharmaceuticals to fund its research in Switzerland, through a Series C private funding. The company is focused on research for the treatment of central nervous system disorders. Since it was founded in May 2002, it...

  • Crunch time for pharma. Martin, John // New Scientist;10/10/2009, Vol. 204 Issue 2729, p24 

    The author reflects on the implications of financial crises for pharmaceutical research. He says that while big pharmaceutical companies have much money, universities are being starved of resources and research funding has decreased. He asserts that the tax system could at least encourage...

  • Companies 'supressed' negative research into child drugs.  // Ecologist;Jun2004, Vol. 34 Issue 5, p8 

    Reports on the suppression of negative results in child drugs trials by pharmaceutical companies. Contents of leaked memo from pharmaceutical company GlaxoSmithKline proving the allegations of data suppression; Percentage of negative reports on cancer drug trials based on a review of previous...

  • Generating and protecting knowledge with electronic laboratory notebooks. Denny-Gouldson, Paul // Pharmaceutical Technology Europe;Jun2006, Vol. 18 Issue 6, p39 

    The article discusses how electronic laboratory notebooks can be an efficient method of recording, accessing, and searching experimetental data and corporate knowledge. The benefits of electronic laboratory notebooks include intellectual property protection, pharmaceutical industry compliance,...

  • Approach to R&D Evolves.  // Chain Drug Review;8/3/2009, Vol. 31 Issue 13, p114 

    The article focuses on the study findings by the Tufts Center for the Study of Drug Development (CSDD) that U.S. pharmaceutical manufactures are finding success at getting more drug candidates into development. According to the study, the share of new self-originated drugs that were eliminated...

  • Rules for Discovery. Lowe, Derek B. // Contract Pharma;Sep2013, Vol. 15 Issue 7, p28 

    The article presents some useful ideas that will help on the early stages of drug discovery. It mentions the need for a team to initiate honest efforts to find new chemical compounds. It cites the importance to check the purity of the early stage of the research projects as it is the phase...

  • The State of Innovation in Drug Development. Kola, I. // Clinical Pharmacology & Therapeutics;Feb2008, Vol. 83 Issue 2, p227 

    The pharmaceutical industry is facing tremendous pressure, not only from payers but as a result of public perception, regulatory hurdles, and the intricacies of research and development (R&D). The latter two are significant in that they affect the number of drugs that may be registered by...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics